Trial · NCT03753763
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) | Safinamide | Any TEAEs | 52 | events | |
| TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) | Placebo | Any TEAEs | 28 | events | |
| TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) | Safinamide | Mild TEAEs | 49 | events | |
| TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) | Placebo | Mild TEAEs | 21 | events | |
| TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) | Safinamide | Moderate TEAEs | 4 | events | |
| TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) | Placebo | Moderate TEAEs | 5 | events | |
| TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) | Safinamide | Severe TEAEs | 3 | events | |
| TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) | Placebo | Severe TEAEs | 4 | events | |
| TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) | Safinamide | Serious TEAEs | 2 | events | |
| TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) | Placebo | Serious TEAEs | 0 | events | |
| TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) | Safinamide | Study drug-related TEAEs | 15 | events | |
| TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) | Placebo | Study drug-related TEAEs | 11 | events | |
| TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) | Safinamide | TEAEs leading to study drug withdrawal | 1 | events | |
| TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) | Placebo | TEAEs leading to study drug withdrawal | 0 | events | |
| TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) | Safinamide | AEs leading to death | 1 | events | |
| TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) | Placebo | AEs leading to death | 0 | events | |
| Change From Baseline to Week 12 in the Goniometric Measurement for Anterior Displacement | Safinamide | 1.3 | Standard Deviation 9.46 | degrees | |
| Change From Baseline to Week 12 in the Goniometric Measurement for Anterior Displacement | Placebo | 0.9 | Standard Deviation 8.01 | degrees | |
| Change From Baseline to Week 12 in the Goniometric Measurement for Lateral Displacement | Safinamide | 1.3 | Standard Deviation 5.08 | degrees | |
| Change From Baseline to Week 12 in the Goniometric Measurement for Lateral Displacement | Placebo | -0.2 | Standard Deviation 4.47 | degrees |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03753763/results